| Bid | 1.61 |
| Market Cap | 227.33M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -5.21 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 6.39 |
| Volume | 179,932 |
| Avg. Volume (20D) | 174,781 |
| Open | 4.15 |
| Previous Close | 4.11 |
| Day's Range | 3.88 - 4.27 |
| 52-Week Range | 2.25 - 7.77 |
| Beta | undefined |
About DSGN
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysf...
Analyst Forecast
According to 3 analyst ratings, the average rating for DSGN stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 24.53% from the latest price.
10 months ago · seekingalpha.com
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call TranscriptDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript
1 year ago · investorplace.com
Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to SqueezeShort squeeze stocks are the talk of Wall Street at the moment. As the banking crisis continues to unfold, some investors are seeking refuge by betting against many well-known losers — and reaping tre...
